A 34-year-old woman with systemic lupus erythematosus (on prednisolone 20 mg daily) presents with a 2-week history of fever, headache, neck stiffness, and photophobia. CSF analysis shows: glucose 35 mg/dL (serum 95 mg/dL), protein 180 mg/dL, WBC 120/μL (70% lymphocytes), negative bacterial culture, and India ink stain positive. Cryptococcal antigen (serum and CSF) is positive. Which antifungal regimen is most appropriate for induction therapy of cryptococcal meningitis in this patient?

Explanation

## Clinical Diagnosis **Key Point:** The patient has cryptococcal meningitis (CM), confirmed by: - CSF findings: hypoglycorrhachia (CSF glucose 35 < serum 95), elevated protein, lymphocytic pleocytosis - India ink stain positive (visualizes yeast with characteristic halo) - Cryptococcal antigen positive in serum and CSF - Risk factor: immunosuppression (SLE on prednisolone 20 mg daily) ## Induction Therapy for Cryptococcal Meningitis **High-Yield:** Amphotericin B deoxycholate (AmB-d) combined with flucytosine is the standard induction regimen for cryptococcal meningitis, especially in immunocompromised patients. ### Mechanism & Rationale **Amphotericin B deoxycholate:** - Binds ergosterol in fungal cell membrane, creating pores → cell lysis (fungicidal) - Achieves adequate CSF penetration (~50% of serum levels) - Rapid fungicidal activity essential for CNS infection - Dosing: 0.7–1.0 mg/kg/day IV **Flucytosine (5-FC):** - Nucleoside analogue → converted to 5-fluorouracil → inhibits thymidylate synthase - Excellent CSF penetration (>90% of serum levels) - Synergistic with amphotericin B (reduces organism burden faster) - Dosing: 100 mg/kg/day in 4 divided doses (25 mg/kg QID) - Monitor serum levels (therapeutic range 25–100 μg/mL) to avoid toxicity **Clinical Pearl:** The combination of AmB-d + 5-FC reduces mortality and improves CSF sterilization compared to AmB-d alone in cryptococcal meningitis. ## Induction vs. Consolidation vs. Maintenance Phases | Phase | Duration | Regimen | Goal | | --- | --- | --- | --- | | **Induction** | 2 weeks | AmB-d (0.7–1.0 mg/kg/day) + 5-FC (100 mg/kg/day) | Rapid CSF sterilization, reduce fungal burden | | **Consolidation** | 8 weeks | Fluconazole 400 mg daily | Continued CNS penetration, transition to oral | | **Maintenance** | ≥1 year (until CD4 >100 if HIV+) | Fluconazole 200 mg daily | Prevent relapse | **Tip:** In this immunosuppressed patient (not HIV), maintenance duration is typically 6–12 months after CSF sterilization, depending on immune reconstitution. ## Why NOT Other Agents? **Fluconazole monotherapy:** - Fungistatic (not fungicidal) — inadequate for CNS infection - Slower CSF sterilization; higher mortality in meningitis - Appropriate only for consolidation/maintenance, not induction **Voriconazole:** - Azole with improved CNS penetration vs. fluconazole - No proven superiority over AmB-d + 5-FC for induction - Reserved for azole-refractory or amphotericin B-intolerant patients **Caspofungin:** - Echinocandin; poor CSF penetration - Ineffective for cryptococcal meningitis - Not recommended for CNS cryptococcal disease **Warning:** Do not use fluconazole or voriconazole monotherapy for induction — this is a common trap. Azoles are fungistatic and insufficient for acute meningitis. ## Monitoring During Induction 1. **Amphotericin B toxicity:** Monitor creatinine, electrolytes (K^+^, Mg^2+^), CBC - Use lipid formulation (AmB-L) if creatinine rises >2× baseline or Cr >2.5 mg/dL 2. **Flucytosine toxicity:** Monitor CBC (bone marrow suppression), LFTs - Reduce dose if serum level >100 μg/mL or WBC <3000 3. **Clinical response:** Repeat CSF culture at 2 weeks (should be sterile) 4. **Intracranial pressure:** Monitor for raised ICP; consider therapeutic lumbar punctures if symptomatic [cite:Harrison 21e Ch 196; Robbins 10e Ch 8]